INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
BK

Balthaser Kevin

Chief Financial OfficerCIK 0001957554

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 0
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A—
99.1K sh
Feb 2, 2026Feb 6, 2026
traded Feb 2, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Aclaris Therapeutics, Inc.Chief Financial Officer · Feb 5, 2026
15
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Grant or award
A
—
346.8K sh
Feb 2, 2026
Feb 6, 2026
traded Feb 2, 2026
+4d
SEC FORM 4

Evidence

13
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
22.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

9
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Tax withholding
F$22K
6,449 sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

21
BK
Balthaser KevinChief Financial Officer
ACRSAclaris Therapeutics, Inc.
Option exercise
M—
22.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence